You are viewing the site in preview mode

Skip to main content

Advertisement

Table 5 Dose effect of interferon-alpha in chronic hepatitis C patients Dose effect of interferon-alpha on end-of-treatment virological response, virological relapse, and sustained virological response in chronic hepatitis C patients with low-, medium-, and high- virological risk

From: High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study

  Low-risk patients, n/N (%)† Medium-risk patients, n/N (%)‡ High-risk patients, n/N (%)§
  3-MU group 6-MU group 3-MU group 6-MU group 3-MU group 6-MU group
End-of-treatment virological response 14/19 (73.7)* 32/32 (100)* 19/39 (48.7)** 50/61 (82.0)** 4/18 (22.2)* 21/31 (67.7)*
Virological relapse 1/14 (7.1) 8/32 (25.0) 16/19 (84.0) 32/50 (64.0) 2/4 (50.0) 17/21 (81.0)
Sustained virological response 13/19 (68.4) 24/32 (75.0) 3/39 (7.7)* 18/61 (29.5)* 2/18 (11.1) 4/31 (12.9)
  1. † Low-risk patients, neither genotype 1b nor pretreatment HCV RNA levels>0.65 Meq/mL.
  2. ‡ Medium-risk patients, either genotype 1b or pretreatment HCV RNA levels>0.65 Meq/mL.
  3. §High-risk patients, both genotype 1b and pretreatment HCV RNA levels>0.65 Meq/mL.
  4. *, P < 0.01; **, P < 0.001.